Form 4 for DCOY Decoy Therapeutics Inc.
Accepted 2026-09-02 17:50:33 ET · period of report 2026-08-31 · accession 0001229055-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-02 17:50 | 2026-08-31 | DCOY | PIERCE FREDERICK II | CEO | A - Grant | $0.00 | +33.5K | 34.8K | +2,409% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-31 | A | A | 33,455 | $0.00 | 34,844 | D | — | — | (F1) Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly increments over the next 36 months. (F2) Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026. |